Clinical trials for dendritic cell vaccine designed to both eradicate cancer cells and prevent disease relapse

Via Scoop.it – Demand Transformation

The Center for Immunotherapy at Roswell Park Cancer Institute has launched a phase I clinical research study of a dendritic cell vaccine designed to both eradicate cancer cells and prevent disease relapse.   The new cell vaccine will be manufactured in the Institute’s new Therapeutic Cell Production Facility using a unique FDA-approved process — making RPCI the first research facility in the U.S. to use a custom-made barrier isolator for vaccine cell production, and the first in the world to use this system in an approved, government-regulated study.
Via nextbigfuture.com